Comments
GVK Biosciences, which provides outsourced pharmaceutical research services, announced on Monday that it has been selected as a preferred provider to a consortium of 14 global product development partners for clinical services in Asia.
Claiming that GVK BIO is the only partner that is headquartered in India, a company release said the partners, funded in part by the Bill and Melinda Gates Foundation, are not-for-profit entities focused on developing drugs for diseases often neglected by mainstream pharmaceutical and biotech companies, such as tuberculosis, malaria, kala-azar, HIV/AIDS, childhood pneumonia and diarrheal diseases.
The 14 partners expect to fund 85 clinical trials in the developing world over the next two years, and India features as a key country.
GVK BIO is working with some of those partners and collaborating with research institutions in India and Bangladesh to help develop preventive and therapeutic modalities that can be introduced into public health programs to reduce the social and economic burden of these diseases.
The company will collaborate with the consortium as a “niche service provider” for clinical monitoring, logistics and safety-monitoring, apart from overall project management, according to chief executive Mr Manni Kantipudi.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.